Metacrine
Latest round
- Series C
Last raised
- Jun 2018
Total raised
- $99M
Investors
- 13
About Metacrine
Metacrine, Inc.Founded in 2014 by Ronald Evans, Metacrine, Inc. specializes in biopharmaceuticals.54 million shares at USD 13 per share.Metacrine, Inc. aims to develop advanced therapeutics addressing unmet medical needs in liver and gastrointestinal disorders.For the year 2021, Metacrine, Inc.Metacrine, Inc. The funds will support ongoing clinical trials and the potential introduction of new therapeutics in the next few years, aiming for broader market presence in North America and Europe by 2023.
Who invested in Metacrine
13 investors across 4 rounds
See all investors in Metacrine
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Metacrine
Who invested in Metacrine?
Metacrine has 13 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Metacrine raised?
Metacrine has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Metacrine last raise money?
Metacrine's most recent round on record is a Series C, in Jun 2018.
What does Metacrine do?
Metacrine is a biotechnology company.
Where is Metacrine headquartered?
Metacrine is headquartered in San Diego, US.
Which VCs invest in companies like Metacrine?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Metacrine's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Metacrine? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.